Is aimovig a biologic?

See the DrugPatentWatch profile for aimovig

Is Aimovig (erenumab) considered a biologic?

Aimovig is a biologic drug. It is a monoclonal antibody (a lab-made antibody designed to bind to a specific target in the body) used to prevent migraines. Because it is an antibody-based medicine made using biologic manufacturing processes, it falls under biologics rather than traditional small-molecule drugs.

Why does it matter for patients and prescriptions?

Treating Aimovig as a biologic affects how it’s regulated and handled compared with pill-based drugs. Biologics typically have specific storage requirements and are given by injection, and they may have different pathways for manufacturing changes and follow-on products than small-molecule medicines.

Is Aimovig the same kind of biologic as vaccines or insulin?

No. “Biologic” is a broad category. Vaccines, insulin, and monoclonal antibodies like Aimovig are all biologics, but they are different types of biologics. Aimovig is specifically a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) pathway.

Could biosimilars be available even if patents still apply?

Biosimilars are possible for biologics when regulatory and patent conditions allow. Whether a biosimilar to Aimovig can enter depends on the specific patents and exclusivity status for erenumab in different markets.

Sources used:
1. https://www.drugpatentwatch.com/